Published: Sat, May 20, 2017
Business | By Max Garcia

Most Recent Analysts Ratings Array BioPharma Inc. (ARRY)


Yet another important factor while evaluating a good buy/sell decision for Array BioPharma Inc.

When it comes to the Analysis of a Stock, Price Target plays a vital role.

An earnings forecast is an analyst's outlook for a company's future quarterly or annual earnings. Stifel Nicolaus maintained Array Biopharma Inc (NASDAQ:ARRY) on Friday, August 5 with "Buy" rating. Jefferies Group LLC restated a "buy" rating and set a $8.00 price target on shares of Array Biopharma in a research report on Wednesday, March 29th. The stock appeared -7.81% below its 52-week highs and is up 7.47% for the last five trades. (ARRY). A frequently used tool among technical stock analysts is the moving average. The analysts, on average, are forecasting a $11.25 price target, but the stock is already up 183.62% from its recent lows.

Array Biopharma Inc (NASDAQ:ARRY) saw a large increase in short interest in the month of March. Quantbot Technologies LP now owns 14,523 shares of the biopharmaceutical company's stock valued at $129,000 after buying an additional 1,423 shares in the last quarter. The company's market cap is $1.36 billion. The stock's current distance from 20-Day Simple Moving Average (SMA20) is 0.84% where SMA50 and SMA200 are -8.42% and 4.66% respectively. According to these analysts, the Low Revenue Estimate for Array BioPharma Inc.is 13 Million and the High Revenue Estimate is 37 Million. Bank Of Ny Mellon has invested 0% of its portfolio in Array Biopharma Inc (NASDAQ:ARRY).

Array BioPharma Inc. (ARRY) have shown a high EPS growth of 8.60% in the last 5 years and has earnings decline of -16.90% yoy. The firm had revenue of $33.28 million for the quarter, compared to analysts' expectations of $38.28 million. ARRY generated revenue of $0 in the same quarter, one year ago.

On the other hand, NeoPhotonics Corporation by far traveled 18.12% versus a 1-year low price of $6.9. The difference between the expected and actual EPS was $-0.05/share, which represents an Earnings surprise of -31.2%. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & worldwide trademark and copyright laws. $231,750 worth of Array Biopharma Inc (NASDAQ:ARRY) was sold by BAUM CHARLES M. The 52-week range is $0.63 to $2.79 and the consensus target price is $2.50. If the share price is now hovering near the 52 week low and the value is achieved in the current past then it can suggest that the price of the shares is likely to go up. EPS breaks down the profitability of the company on a single share basis. It has a 36-month beta of 2.25, so you might be in for a bumpy ride.

Several hedge funds have recently modified their holdings of the company. Array BioPharma had 9 analyst reports since June 3, 2016 according to SRatingsIntel. The rating was reinitiated by Mackie with "Buy" on Monday, November 30. Sol Capital Management Co acquired 21,576 shares as Teva Pharmaceutical Industries (TEVA)'s stock 0.00%. Aperio Group LLC raised its position in Array Biopharma by 13.6% in the third quarter.

While looking at the Stock's Performance, Array BioPharma Inc. now shows a Weekly Performance of -0.12%, where Monthly Performance is 1.12%, Quarterly performance is -27.19%, 6 Months performance is 16.45% and yearly performance percentage is 174.07%. Given that its average daily volume over the 30 days has been 4.12 million shares a day, this signifies a pretty significant change over the norm.

Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC).

Like this: